Practice · Transplant Sciences

A transplant programme's growth engine, orchestrated end-to-end.

Living-donor coordination, cadaveric activation, international patient corridors and BMT candidacy — one pipeline, four disciplines, zero PII leaks.

For Chiefs of Transplant Sciences, Programme Directors and MDs of multi-organ transplant super-specialty hospitals.

Request a Transplant Pipeline Blueprint →Review case evidence

International Patient Mix

22%

Of programme revenue

LDLT Volume

+64%

12-mo cohort

Renal Tx Conversions

2.4×

Dialysis → transplant

Donor Coordination SLA

< 21 days

Screening → cross-match

Procedure-level demand engineering

We target the procedures that move your P&L, not the ones that fill the OPD queue.

CATCHMENT TIER · PRICE RESTATEMENT

ARPU differs materially between Metro, Tier-2 and Tier-3 catchments. Switch tier to restate every procedure band against the payer mix and package ceilings we observe in that market — not a single all-India number.

Viewing Metro / Tier-1 · Representative catchments: Delhi NCR, Mumbai, Bengaluru, Chennai, Hyderabad, Kolkata, Pune.

Liver Transplant (LDLT + DDLT)

₹22 L–35 L

ESLD → LDLT candidacy funnel

Renal Transplant

₹18 L–28 L

CKD / dialysis → transplant path

BMT / Stem Cell

₹18 L–45 L

Haematological malignancy funnel

Living-Donor Coordination

Bundled

Family-network activation & consent

International Patient Pathway

Multi-programme

Country-corridor referral network

Post-Transplant Long-term Care

₹40K–1.2 L / yr

5-year continuity revenue

Methodology. Base bands reflect RDV's engagement dataset across 47 super-specialty hospitals, reconciled against CGHS/ECHS package rates, state-scheme ceilings (Ayushman Bharat PM-JAY, CMCHIS, YSR Aarogyasri) and empanelled TPA grids. Tier multipliers applied: Metro 1.00× · Tier-2 0.72× · Tier-3 0.55×. Actuals swing with payer mix, consultant-fee split and implant/consumable choice — the written Blueprint restates every band against your own HIS billing history before any spend is committed.

Clinical referral pathway

Intent → triage → consult → admission. Instrumented at every gate.

01 · Intent capture
Disease-stage content in Hindi, Bengali, Arabic, French (per corridor).
02 · Clinical + financial pre-qualification
Report review + financial pre-authorization before travel.
03 · Coordinator handoff
Dedicated transplant coordinator; visa & logistics partner integration.
04 · Programme instrumentation
Work-up, cross-match, surgery, ICU, discharge tracked as a single episode.

Case snapshot

22% international IP mix; +64% LDLT volume.

A representative RDV engagement in the Transplant Sciences practice line. Individual results vary by catchment, clinical capacity and payer mix.

Setting: Multi-organ transplant institute, 420 beds
Duration: 18 months
Cohort: n = 1,120 pre-qualified transplant enquiries
Outcome: 22% international IP mix; +64% LDLT volume

Figures engagement-verified against hospital HIS. No outcome guarantees implied; per NMC advertising guidelines.

Why Chiefs of Transplant choose RDV

Trust is earned in the operating logic, not the pitch deck.

Corridor-specific programmes

Each country gets its own language, financial pre-auth workflow and coordinator team. Not one 'medical tourism' campaign.

Empanelled legal review

Every donor-facing asset reviewed by transplant-law counsel. State authorization committee alignment documented.

Financial pre-authorization first

No patient boards a flight without approved estimate, insurance verification and coordinator assignment.

Clinical-readiness gate

We qualify your ICU, immunology and haematology depth before we accept the engagement. Growth without capacity is a governance risk we refuse.

From an engagement

"They turned down our first proposal — said our BMT unit wasn't ready. When we re-engaged 8 months later they'd been proven right, and the pipeline they then built compounded quarterly."

— Managing Director · 420-bed multi-organ transplant institute

Attribution anonymised per client confidentiality; engagement code verifiable in the founder-led review.

Talk directly to the founding partner who ran this engagement.

Request a Transplant Blueprint →

48-hour founder-led review. Fixed-scope. No lock-in.

Clinical authority

Content your clinicians will co-sign.

Transplant surgeon narrative library (technique + outcome data disclosure)
Living-donor SOP page (candidacy → surgery → follow-up)
Multilingual patient-education arm across corridor languages

Compliance posture

Every asset, every claim, medically reviewed.

THOTA-compliant donor communications
State authorization committee (SAC) documentation flow visible
International patient DPDP + destination-country privacy alignment

Catchment note: Purpose-built corridors: GCC (Dubai, Muscat, Riyadh), East Africa (Nairobi, Addis Ababa, Kampala), SAARC (Dhaka, Kathmandu, Colombo).

The 21-day diagnostic

What the fixed-scope engagement actually contains — for Transplant.

No mystery, no scope creep. Each week is instrumented and delivered against a checklist your MD and Chief signs.

Week 1–2
Clinical-readiness audit: ICU, immunology, haematology, SAC governance.
Week 3
Corridor selection & country-referrer mapping (GCC / East Africa / SAARC).
Week 4
Financial pre-auth workflow design; coordinator team scoping.
Week 5
Founder-led readiness review with MD and Chief of Transplant Sciences.

Where we compound

The unfair edge — for Transplant specifically.

Only consultancy operating corridor-specific programmes with in-language coordinators
Clinical-readiness gate that will decline engagements ahead of capacity
Multilingual (Hindi, Bengali, Arabic, French) patient-education arm

Practice guarantees

What we commit to in writing.

Fixed-scope diagnostic — no retainer, no annual lock-in
HIS-verified attribution — every claimed admission traceable to source
No media markup — you see raw platform invoices at cost
Founder-led — the partner who scopes the engagement does the work

Objections we hear

The three questions MDs ask before signing.

We keep our answers on the record. If yours isn't here, ask it in the qualification form — the founding partner replies personally within 48 hours.

We just want more LDLT cases — do we need all this infrastructure?

Yes. LDLT volume without a coordinator, financial pre-auth and SAC-aligned donor communication generates regulatory risk, not revenue. We build the substrate first; volume compounds after.

Our international patient desk already handles inbound.

Handling inbound is fulfilment. Generating pre-qualified, financially-pre-authorised international demand in the source country is a separate discipline. We build the second; your desk does what it does best with the first.

BMT ramp is too slow to justify the fee.

Correct in year one. Year two onward, haematologist-referrer trust compounds — because BMT patients enter the ecosystem via lymphoma, leukaemia and myeloma diagnosis years earlier. Long-cycle referrals, once built, don't churn.

FAQ

The questions Chiefs of Transplant ask us first.

If yours isn't here, put it in the qualification form — our founding partner will answer it in the 48-hour review.

How do you build international patient volume for transplant?+

Country by country. Each corridor gets its own language, clinical content, financial pre-authorization workflow and coordinator team. Aggregate 'medical tourism' campaigns underperform corridor-specific programmes by 3-5×.

How do you handle THOTA-sensitive donor communication?+

All donor-facing content is reviewed by empanelled legal counsel and mirrors state authorization committee (SAC) documentation. We do not generate leads for donation — we support voluntary living-donor education for identified family relationships.

What ramp-up should we expect for a new BMT programme?+

Typically 12-18 months to case volume that supports full BMT unit economics. The bottleneck is haematologist-referrer trust, which is a long-cycle relationship-building exercise, not a media buy.

Do you take on transplant clients without a mature ICU?+

No. Transplant demand ahead of clinical capacity is a governance and outcome risk. We qualify clinical readiness in the diagnostic phase before recommending engagement.

Next step